Plant extract from low-thc cannabis for the treatment of disease

Abstract

The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of Cannabis sativa subsp. sativa for the treatment of disease. The invention further relates to the production of the extract and pharmaceutical compositions comprising said extract and the uses thereof.

1 - 16 . (canceled) 
     
     
         17 . A plant extract from at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of a low-tetrahydrocannabinol (THC) variety of  Cannabis sativa  subspecies  sativa,    wherein the THC content of the extract is less than 0.5 wt.-%, for the treatment of diseases selected from the group neurodeimitis, contact eczema, allergies, the prevention or treatment of phototoxic reactions, the treatment of inflammatory, itching dermatoses, rosacea, perioral deiniatitis, acne, acne conglobata, psoriasis (vulgaris, arthropathica, pustulosa), mosquito bites, skin atrophy, allergic rhinitis, privinismus, conjunctivitis, otitis externa, bronchial asthma, Crohn's disease, ulcerative colitis, sarcoidosis, or inflammatory-rheumatic diseases of the soft tissue or joints, or external mycoses.   
     
     
         18 . The plant extract as claimed in  claim 17 , wherein the skin atrophy cortisone-related skin changes. 
     
     
         19 . The plant extract according to  claim 17 , wherein solvents or mixtures of solvents are used as extraction medium for extracting THC from the plant, the solvents being selected from the group comprising water, table salt solution, low-molecular weight alcohols, acetone, esters, and ethers. 
     
     
         20 . The plant extract according to  claim 18 , wherein approximately 0.9% table salt solution, 90% ethanol, or 70% isopropanol is used as the extraction medium. 
     
     
         21 . The plant extract according to  claim 17 , wherein the low-THC variety of  Cannabis sativa  subspecies  sativa  is the variety Futura 75. 
     
     
         22 . The plant extract according to  claim 17 , wherein the THC content of the extract is less than 2% (wt.-%) THC content. 
     
     
         23 . The plant extract according to  claim 17 , wherein the THC content of the extract is less than 0.5 to 0.2% (wt.-%) THC content. 
     
     
         24 . The plant extract according to  claim 17 , wherein the THC content of the extract is 0.1 or 0% (wt.-%) THC content. 
     
     
         25 . A method for the production of a plant extract from at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of a low-tetrahydrocannabinol (THC) variety of  Cannabis sativa  subspecies  sativa , wherein the THC content of the extract is less than 0.5 wt.-%, comprising the steps of
 a) drying the flowers, flower-proximal leaves, stalks, roots, or seeds,   b) pulverizing the flowers, flower-proximal leaves, stalks, roots, or seeds, and   c) extracting the flowers, flower-proximal leaves, stalks, roots, or seeds with at least one solvent.   
     
     
         26 . The method according to  claim 25 , wherein the extraction in c) comprises the steps of
 c-1) admixing the flowers, flower-proximal leaves, stalks, roots, or seeds for 24 hours-48 hours with an extraction medium at room temperature, and   c-2) filtering the extract.   
     
     
         27 . The method according to  claim 25 , further comprising the step of
 d) freeze-drying of the acquired extract or   e) vacuum extraction of the acquired extract.   
     
     
         28 . The method according to  claim 25 , wherein solvents or mixtures of solvents are used as the extraction medium, the solvents being selected from the group comprising water, table salt solution, low-molecular-weight alcohols, acetone, esters, and ethers. 
     
     
         29 . The method according to  claim 28 , wherein 0.9% table salt solution, 90% ethanol, or 70% isopropanol is used as the extraction medium. 
     
     
         30 . The method according to  claim 25 , wherein the low-THC variety of  Cannabis sativa  subspecies  sativa  is the variety Futura 75. 
     
     
         31 . A pharmaceutical composition, comprising a plant extract made of at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of one and/or multiple low-THC varieties of  Cannabis sativa  subspecies  sativa , produced according to  claim 25 , and further pharmaceutically suitable aids and/or additives. 
     
     
         32 . A cosmetic or deimatological composition for topical use, comprising a plant extract made of at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of one and/or multiple low-THC varieties of  Cannabis sativa  subspecies  sativa , wherein the THC content is less than 0.5 wt.-%, produced according to  claim 25 , and further pharmaceutically suitable aids and/or additives. 
     
     
         33 . A method for the treatment of neurodennitis, contact eczema, allergies, or for the prevention or treatment of phototoxic reactions, or for the treatment of inflammation, itching dertnatoses, rosacea, perioral dermatitis, acne, acne conglobata, psoriasis (vulgaris, arthropathica, pustulosa), mosquito bites, skin atrophy (in particular also cortisone-related skin changes), allergic rhinitis, privinismus, conjunctivitis, otitis extema, bronchial asthma, Crohn's disease, ulcerative colitis, sarcoidosis, or inflammatory-rheumatic diseases of the soft tissue or joints, or external mycoses, said method comprising
 (a) obtaining a plant extract from at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of a low-tetrahydrocannabinol (THC) variety of  Cannabis sativa  subspecies  sativa , wherein the THC content is less than 0.5 wt.-%, or a pharmaceutical composition containing said plant extract, and   (b) administering said extract or pharmaceutical to a patient experiencing neurodeitnitis, contact eczema, allergies, phototoxic reactions, inflammation, itching dermatoses, rosacea, perioral derniatitis, acne, acne conglobata, psoriasis (vulgaris, arthropathica, pustulosa), mosquito bites, skin atrophy, allergic rhinitis, privinismus, conjunctivitis, otitis externa, bronchial asthma, Crohn's disease, ulcerative colitis, sarcoidosis, or inflammatory-rheumatic diseases of the soft tissue or joints, or external mycoses.   
     
     
         34 . A method for the treatment of therapy failures and/or refusers of a therapy using cortisone preparations and/or calcineurin inhibitors and of side effects of cortisone preparations and/or calcineurin inhibitors or for the replacement therapy for the treatment using cortisone preparations and/or calcineurin inhibitors, or the prevention or treatment of phototoxic reactions, said method comprising:
 (a) obtaining a plant extract from at least one of: the flowers, flower-proximal leaves, stalks, roots, and seeds of a low-tetrahydrocannabinol (THC) variety of  Cannabis sativa  subspecies  sativa , wherein the THC content of said extract is less than 0.5 wt.-%, or a pharmaceutical composition containing said plant extract, and   (b) administering said extract or pharmaceutical to a patient experiencing at least one of said conditions.   
     
     
         35 . The method as claimed in  claim 34 , wherein the replacement therapy for the treatment using cortisone preparations and/or calcineurin inhibitors is for the replacement of cortisone preparations and/or calcineurin inhibitors upon the treatment of neurodennitis, allergies, contact eczema, inflammatory, itching dermatoses, rosacea, perioral delinatitis, acne, acne conglobata, psoriasis (vulgaris, arthropathica, pustulosa), mosquito bites, skin atrophy (in particular also cortisone-related skin changes), allergic rhinitis, privinismus, conjunctivitis, otitis externa, bronchial asthma, Crohn's disease, ulcerative colitis, sarcoidosis, inflammatory-rheumatic diseases, mycoses.